Claudia Kucherer
Overview
Explore the profile of Claudia Kucherer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanke K, Faria N, Kuhnert D, Yousef K, Hauser A, Meixenberger K, et al.
J Virol
. 2019 Apr;
93(12).
PMID: 30944175
HIV-1 non-B infections have been increasing in Europe for several years. In Germany, subtype A belongs to the most abundant non-B subtypes showing an increasing prevalence of 8.3% among new...
2.
Machnowska P, Meixenberger K, Schmidt D, Jessen H, Hillenbrand H, Gunsenheimer-Bartmeyer B, et al.
PLoS One
. 2019 Jan;
14(1):e0209605.
PMID: 30650082
The prevalence of transmitted drug resistance (TDR) in antiretroviral therapy (ART)-naïve individuals remains stable in most developed countries despite a decrease in the prevalence of acquired drug resistance. This suggests...
3.
Nielsen S, Gassowski M, Wenz B, Bannert N, Bock C, Kucherer C, et al.
Hepatol Med Policy
. 2018 Oct;
1:8.
PMID: 30288312
Background: People who inject drugs (PWID) are disproportionately affected by both HIV and hepatitis C infection (HCV). Awareness of infection status is essential to ensure linkage to appropriate healthcare for...
4.
Derks L, Gassowski M, Nielsen S, An der Heiden M, Bannert N, Bock C, et al.
Int J Drug Policy
. 2018 Jul;
59:54-62.
PMID: 30005420
Background: High prevalence of drug use and injection-related risk behaviours have been reported among former Soviet Union (FSU)-migrants. To investigate hepatitis C (HCV) and HIV seroprevalence and related risk behaviours...
5.
Meixenberger K, Yousef K, Smith M, Somogyi S, Fiedler S, Bartmeyer B, et al.
Virol J
. 2017 Nov;
14(1):223.
PMID: 29137637
Background: Detailed knowledge of the evolutionary potential of polymorphic sites in a viral protein is important for understanding the development of drug resistance in the presence of an inhibitor. We...
6.
Hohn O, Norley S, Kucherer C, Bazarbachi A, El Hajj H, Marcus U, et al.
PLoS One
. 2017 Aug;
12(8):e0183496.
PMID: 28829831
Background: Although human T-lymphotropic virus (HTLV) is transmitted via the same routes as human immunodeficiency virus (HIV), its worldwide seroprevalence differs drastically because HTLV is transmitted mainly via infected cells...
7.
Hofmann A, Hauser A, Zimmermann R, Santos-Hovener C, Batzing-Feigenbaum J, Wildner S, et al.
BMC Infect Dis
. 2017 Jul;
17(1):484.
PMID: 28693564
Background: The HIV surveillance system in Germany is based on mandatory, anonymous notification of newly diagnosed HIV cases by laboratories. Because the time between HIV infection and the diagnosis of...
8.
Ahrenstorf G, Low H, Kniesch K, Ordonez D, Meyer-Olson D, Ahmad F, et al.
AIDS
. 2016 Oct;
31(1):25-34.
PMID: 27755104
Objective: The aim of this study is to analyse the influence of LILRA3 and the genetic leukocyte immunoglobulin-like receptor 3 (LILRA3) deletion on transmission and clinical course of HIV infection....
9.
Wenz B, Nielsen S, Gassowski M, Santos-Hovener C, Cai W, Ross R, et al.
BMC Public Health
. 2016 Sep;
16:927.
PMID: 27595567
Background: People who inject drugs (PWID) are at increased risk of acquiring and transmitting HIV and Hepatitis C (HCV) due to sharing injection paraphernalia and unprotected sex. To generate seroprevalence...
10.
Morozov V, Morozov A, Schurmann D, Jessen H, Kucherer C
Virus Genes
. 2016 Aug;
35(3):877.
PMID: 27517683
No abstract available.